The treatment with PPAR-γ agonist pioglitazone promotes IFN-γ production in tumor-infiltrating iNKT cells and helps to prolong the survival of tumor-bearing mice by enhancing the antitumor response (153) (Figure 5). Here, IFNG is linked to neoplasm.